TELA Bio (NASDAQ:TELA) Given New $1.00 Price Target at Piper Sandler

TELA Bio (NASDAQ:TELA) had its price objective reduced by investment analysts at Piper Sandler from $1.25 to $1.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 42.86% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group reduced their price objective on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of TELA Bio in a research note on Thursday, January 22nd. Loop Capital set a $3.00 target price on shares of TELA Bio in a report on Monday, December 1st. Finally, Lake Street Capital decreased their price target on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.60.

TELA Bio Stock Performance

Shares of TELA traded down $0.06 during mid-day trading on Wednesday, reaching $0.70. The company’s stock had a trading volume of 480,027 shares, compared to its average volume of 178,372. The company has a current ratio of 3.30, a quick ratio of 2.62 and a debt-to-equity ratio of 26.65. TELA Bio has a 1-year low of $0.62 and a 1-year high of $2.20. The business has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $1.14. The stock has a market cap of $28.24 million, a P/E ratio of -0.78 and a beta of 0.88.

TELA Bio (NASDAQ:TELA) last posted its earnings results on Tuesday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. TELA Bio had a negative return on equity of 272.13% and a negative net margin of 50.61%.The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $21.04 million. As a group, equities research analysts anticipate that TELA Bio will post -1.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in TELA Bio by 101.4% during the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after purchasing an additional 64,800 shares during the period. Susquehanna International Group LLP boosted its stake in TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after buying an additional 72,594 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of TELA Bio by 161.3% during the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after purchasing an additional 21,781 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of TELA Bio during the fourth quarter worth $48,000. Finally, WealthTrust Axiom LLC increased its holdings in TELA Bio by 39.1% in the 4th quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after purchasing an additional 90,650 shares in the last quarter. Institutional investors own 94.35% of the company’s stock.

More TELA Bio News

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: TELA reported Q4 EPS of ($0.16), beating the consensus by $0.02, showing slight operating improvement; revenue was $20.87M (very near estimates). Earnings Summary
• Positive Sentiment: Management is targeting at least 8% revenue growth in 2026 and described commercial initiatives to drive growth—this provides a clear, modest growth outlook for investors. Growth Guidance
• Neutral Sentiment: Full Q4 materials and call transcripts are available (company press release and multiple transcripts), enabling investors to dig into revenue drivers, margins and KOL/commercial commentary. Press Release
• Negative Sentiment: Two brokers lowered price targets to $2 (Lake Street and Canaccord) — both retained “buy” ratings but the cuts reduce near‑term upside expectations and likely pressured the stock. Analyst Notes TickerReport
• Negative Sentiment: Revenue narrowly missed consensus and the company remains materially unprofitable (negative net margin and very negative ROE), keeping valuation and investor sentiment fragile for this small‑cap name. Revenue / Profitability Note

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.